Dr. Ami Shah is a pharmacist who is specialized in Critical Care in New York, New York. Patients can reach her at 1111 Amsterdam Ave, New York or contact her on 732-589-6437. Active license number of Dr. Ami Shah is 060411 for Critical Care in New York. Dr. Ami Shah is a licensed pharmacist who has demonstrated specialized knowledge and skill in the delivery of patient care services by pharmacists, as integral members of interprofessional teams, working to ensure the safe and effective use of medications in critically ill patients.
Complete Profile:
Dr. Ami Shah speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Dr. Ami Shah
Specialization:
Critical Care
Credentials:
PHARMD, BCCCP
Gender:
Female
Location:
1111 Amsterdam Ave, New York, New York, 10025-1716
Phone:
732-589-6437
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Dr. Ami Shah are as mentioned below.
NPI Number:
1497370936
NPI Enumeration Date:
10 Jun, 2020
NPI Last Update On:
10 Jun, 2020
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Ami Shah are as mentioned below.
Specialization
License Number
State
Status
Critical Care
060411
New York
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
1111 Amsterdam Ave, New York, New York
Zip:
10025-1716
Phone Number:
--
Fax Number:
--
Patients can reach Dr. Ami Shah at 1111 Amsterdam Ave, New York, New York or can call on phone at 732-589-6437.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.